home / stock / pmcb / pmcb news

PMCB News and Press, PharmaCyte Biotech Inc. From 09/25/19

Stock Information
Company Name: PharmaCyte Biotech Inc.
Stock Symbol: PMCB
Market: OTC
Website: pharmacyte.com
Menu
PMCB PMCB Quote PMCB Short PMCB News PMCB Articles PMCB Message Board
Get PMCB Alerts

News, Short Squeeze, Breakout and More Instantly...
PMCB - PharmaCyte Biotech Releases Shareholder Update Call Playback Information

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that an audio recording of the company’s shareholder update ca...
PMCB - PharmaCyte Biotech's Pancreatic Cancer Therapy Production in Final Days of Key Manufacturing Run

NEW YORK, NY, Sept. 23, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) and its partner, Austrianova, along with the company’s cellular biologist, David Judd, are all more confident than ever that they have a product that can succeed in a U.S. FDA clinical trial for locally...

PMCB - PharmaCyte Biotech Provides Information on Upcoming Shareholder Update Call

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today provided the call information for PharmaCyte’s upcoming sha...

PMCB - PharmaCyte Biotech Releases Results of Shareholder Meeting and Provides Information on Upcoming Shareholder Update Call

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced the results of the Special Shareholder Meeting and provi...
PMCB - PharmaCyte Biotech Holding Special Shareholder Meeting Today

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced a reminder for shareholders that this morning a Special ...

PMCB - PharmaCyte Biotech Releases New Video Documentary of Its Pancreatic Cancer Treatment

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that it has released a new video documentary of its panc...

PMCB - PharmaCyte Biotech Confirms Dr. Manuel Hidalgo Will Be Principal Investigator for Clinical Trial in Pancreatic Cancer

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that nationally and internationally renowned clinician a...
PMCB - PharmaCyte Biotech Releases Proxy Statement Related to Special Shareholder Meeting

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that its proxy statement related to the announced Specia...

PMCB - PharmaCyte Biotech to Hold Special Shareholder Meeting

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that it will hold a Special Shareholder M...

PMCB - PharmaCyte Biotech and UTS Creating Advanced Version of Melligen Cells to Treat Diabetes

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced it has entered into a new research agreement with t...
Previous 10 Next 10